Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis

SIMPLE SUMMARY: Febrile neutropenia is the serious side-effect associated with myelosuppressive chemotherapy. Filgrastim, the first granulocyte colony-stimulating factor (G-CSF) was approved by the Food and Drug Administration for the treatment of neutropenia. Subsequently, pegfilgrastim (long-actin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rastogi, Shruti, Kalaiselvan, Vivekananda, Ali, Sher, Ahmad, Ajaz, Guru, Sameer Ahmad, Sarwat, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533340/
https://www.ncbi.nlm.nih.gov/pubmed/34681169
http://dx.doi.org/10.3390/biology10101069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533340/
https://www.ncbi.nlm.nih.gov/pubmed/34681169
http://dx.doi.org/10.3390/biology10101069

Ejemplares similares